Kornimate/medical-research-clean huggingface dataset:
pelvic floor muscles and success in the surgical treatment of stress urinary incontinence and pelvic organ prolapse

Conditions: Stress Urinary Incontinence; Pelvic Organ Prolapse; Pelvic Floor Disorders

Summary: the aim of the study is evaluation of the efficiency of pelvic floor muscles in the context of surgical outcomes in the treatment of stress urinary incontinence and pelvic organ prolapse.


Eligibility criteria:
inclusion criteria: * premenopausal and postmenopausal women * stress urinary incontinence * pelvic organ prolapse exclusion criteria: - previous surgical interventions due to stress urinary incontinence or pelvic organ prolapse
efficacy of physiotherapy on the health and quality of life of the rheumatic patient

Conditions: Rheumatic Arthritis

Summary: despite leading cause of morbidity, treatment strategies for rheumatic diseases are geared almost exclusively toward medical-pharmacological area away from offering the patient the possibility of an interdisciplinary approach to their disease. present study test whether treatment of physiotherapy reduces stiffness and pain inherent in rheumatic disease and improve their quality of life related to health.


Eligibility criteria:
inclusion criteria: * patients older than 18 years * history of rheumatoid arthritis (ra) symptoms for less than 7 years * had ra by american college of rheumatology (acr) criteria * acr functional ra class i, ii or iii * hemoglobin more than 8g/dl without evidence of active bleeding * positive for rheumatoid factor (rf) or anti cyclic citrullinated protein * standard conventional medicine were allowed within the approved dosage regimen exclusion criteria: * connective tissue disease * any other alternative or complementary medicine with in last 3 months. * corticosteroid, disease modifying medicines * poorly controlled diabetes, hypertension, hepatitis, cardiac disease, liver diseases, carcinoma, drug abuse

Keywords: pain functional capacity quality of life
feasibility of high intensity interval training in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the focus of this pilot study is to evaluate the feasibility of utilizing an evidenced-based high intensity interval training program (hiit) to improve physical function in patients with knee osteoarthritis (oa).

all participants will be assigned to the single-arm of the study in which all participants will receive 12 weeks of hiit, delivered twice per week. the primary outcome will examine the feasibility and acceptability of the 12 week hiit program in patients with knee oa symptoms ranging from mild to severe. the investigators will determine adherence to and tolerability of hiit, acceptability, and recruitment and retention rates during the 12 week program. additional outcomes will include physical function, knee oa symptomatic burden (pain), static standing balance, isometric knee extensor and flexor strength, cardiorespiratory fitness, and body composition.

Eligibility criteria:
inclusion criteria: * between the ages of 40 and 75 years old * body mass index of 18.5-50 kg/m² * exhibits symptomatic knee oa, defined as a diagnosis of knee oa, as identified from university of north carolina electronic medical records, and current knee symptoms in at least one knee, having a minimum score of 6 out of 20 on the western ontario and mcmasters universities osteoarthritis index (womac) pain subscale. exclusion criteria: * individuals diagnosed with a cardiovascular condition restricting exercise * individuals currently meeting department of health and human services guidelines for physical activity (≥ 150 minutes per week * individuals currently doing hiit * individuals currently participating in physical therapy for knee oa * individuals currently participating in another oa intervention study * received a corticosteroid or hyaluronic acid intra-articular injection in the knee during the previous 3 weeks or scheduled for during the intervention * diagnosis of gout in the knee * diagnosis of rheumatoid arthritis * diagnosis of fibromyalgia * other systemic rheumatic disease * severe dementia or other memory loss * active diagnosis of psychosis or uncontrolled substance abuse disorder * hospitalization for a stroke, heart attack, or heart failure, or had surgery for blocked arteries in the past 3 months * total joint replacement knee surgery, other knee surgery, meniscus tear, or anterior cruciate ligament (acl) tear in the past 6 months * on a waiting list for total joint replacement * severely impaired hearing or speech * pregnant or planning to become pregnant while enrolled in the study * inability to speak english * serious or terminal illness as indicated by referral to hospice or palliative care * nursing home residence * inability to ride a stationary bike * any other health problems that would prohibit safe participation in the study * ekg results ekg suggesting the individual would not be able to safely participate in this study

Keywords: knee osteoarthritis
study of anlotinib combined with docetaxel in non-driver mutation non-squamous nsclc: the save study

Conditions: Non-Squamous Non Small Cell Lung Cancer

Summary: the purpose of this study is to evaluate the effectiveness and safety of anlotinib combined with docetaxel in progress after first line standard cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer

the purpose of this study is to evaluate the effectiveness and safety of anlotinib combined with docetaxel in progress after first line standard cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer .according to the result of tax317,the orr of second line standard chemotherapy was 5- 8%. we expect the orr was 20%. using pass11, we calculated the sample size of this study was 39 , according to 10% censoring,the expected sample size is 43.

Eligibility criteria:
inclusion criteria: * 18，pathologically proven non squamous non small cell lung cancer * no-drive gene mutaion (egfr、alk、ros1） by ngs * progress after second line * ps score 0-2 exclusion criteria: * patients received second line treatment * patients received treatment of anlotinib or docetaxel * patients with contraindication of chemotherapy * pregnant or breast feeding women

Keywords: anlotinib combined with docetaxel
the effect of a single spinal manipulation on cardiovascular autonomic activity

Conditions: Manipulation, Spinal

Summary: this study evaluates the effect of a single high-velocity low-amplitude spinal manipulation on both cardiovascular autonomic activity and pressure pain thresholds. it is a cross-over study, thus each participant will undergo both interventions (spinal manipulation and sham manipulation). both interventions will be separated by a 48 h wash-out period.

several systematic reviews have shown that spinal manipulations may have an immediate effect on autonomic nervous system activity (e.g. increase in skin sympathetic nerve activity) and on sensitivity to experimentally-induced pain (e.g. increase in pressure pain threshold). it is generally unknown i) if these supposed effects last after the immediate post intervention period and ii) if there is a statistical relationship between them, considering that pain and autonomic networks are closely connected and interact at the peripheral, spinal and supra-spinal levels. the primary aim of the study is to assess every single effect immediatly and at short-term after the intervention. the secondary aim is to assess the bivariate statistical relationship between cardiovascular autonomic activity and sensitivity to experimentally-induced pain after the intervention. cardiovascular autonomic nervous system activity is assessed with both heart rate and systolic blood variabilities sensitivity to experimentally-induced pain is measured using pressure pain threshold.

Eligibility criteria:
inclusion criteria: * first-year chiropractic student at ifec * volunteer * healthy (no pain, no disease) exclusion criteria: * counter indications to spinal manipulation * drugs intakes (pain killers or beta-blockers) * food, caffeine and tobacco intakes during the previous hour * alcohol intake and performance of strenuous physical activity the day of the experimentation
benefit of the digital workflow for screw-retained single implant restorations

Conditions: Tooth Loss

Summary: the aim of this research project is emphasize the benefit of the digital workflow compared to conventional impressions and crown processing with standard la procedures. the objectives of the present study are to measure and compare the global cost, the time spent in the dental chair and in the lab and the fit of both digital and conventional workflow. additionally, patient centered outcomes will be recorded.


Eligibility criteria:
inclusion criteria: * subject must have voluntarily signed the informed consent form before any study related action * age: 18 with one or more missing teeth in the maxillary area, seeking for implant therapy. * men/women * in good systemic health (asa i/ ii) * present with no contra indication against oral surgical interventions * patients required replacement of a single missing tooth. the tooth at the implant site(s) must have been extracted or lost at least 12 weeks before the date of implantation. * at least 10 mm of bone in the vertical dimension * at least 6 mm of bone in the bucco-lingual dimension. * no need for bone augmentation procedure in any of the dimensions * full mouth plaque score (fmpi) lower or equal than 25% exclusion criteria: * autoimmune disease require medical treatment * medical conditions requiring prolonged use of steroids * use of bisphosphonate intravenously or more then * infection (local or systemic) - patient with gingivitis or active local infection will undergo a medical treatment prior to his entrance to the study, each individual will be evaluated prior to study procedure for suitability, in case of systemic infection the evaluation will be based on medical anamneses, and if necessary will be referred to relevant medical tests. * current pregnancy or breastfeeding women * alcoholism or chronically drug abuse * immunocompromised patients * uncontrolled diabetes * smokers * prisoners
parent led implementation of a vr social skills training program for children with asd

Conditions: Autism Spectrum Disorder

Summary: the goal of this interventional trial is to establish training protocols to show feasibility of training parents and caregivers to administer the vr protocol. the primary objective is to evaluate the effects of treatment with floreo building social connections (bsc) on the aim, a parent report survey that assesses core symptoms of asd. the secondary objective is to explore the changes in social skills over time by using a multimethod outcomes battery. the investigators will evaluate the effect of treatment with floreo bsc on the childhood autism rating scales (cars-2) in the study patient population. additional secondary objectives include evaluation of the effects of treatment on adaptive skills as measured by the vineland-3. participants will be asked to complete questionnaires and utilize the vr program at clinic and at home.


Eligibility criteria:
inclusion criteria: * patients or legally authorized representatives must provide written informed consent and be willing and able to comply with study procedures. participants must provide informed assent as clinically appropriate. * a diagnosis of autism spectrum disorder on the basis of the clinical judgement of a qualified clinician according to dsm-5 criteria, supported by either the autism diagnostic observation schedule or the autism diagnostic interview-revised. * participants must be able to tolerate vr therapy in the judgement of parent or caregiver and study staff. * female participants must either be unable to become pregnant (e.g., premenarchal, surgically sterile, etc.) or agree to use a highly effective method of contraception (e.g., intrauterine device, oral contraceptives, condom or diaphragm with spermicides, contraceptive sponge) from 28 days before the baseline visit to 45 days after the last treatment session. females of childbearing potential must have a negative urine human chorionic gonadotropin pregnancy test at the screening visit. exclusion criteria: * history of photosensitive epilepsy or demonstrated photoparoxysmal response on prior electroencephalogram. * active diagnosis of migraine headache or migraine variant (abdominal migraine, cyclic vomiting syndrome) which is not adequately controlled by medication or other therapy. * history of balance disorder including vertigo, motion sensitivity, or ataxia. vestibular sensory deficits are not necessarily exclusionary. * primary sensory impairment (blindness, deafness). * motor disorder that would interfere with vr engagement.
study to evaluate the safety, tolerance, pharmacokinetics and preliminary efficacy of ibi346#cibi346y002#

Conditions: Relapsed/Refractory Multiple Myeloma

Summary: an open label, single-arm clinical study evaluating the safety and efficacy of ibi346 infusion in relapsed/refractory multiple myeloma


Eligibility criteria:
inclusion criteria: 1. according to the multiple myeloma diagnostic criteria of the international myeloma working group (imwg), there is the initial diagnosis of multiple myeloma. 2. subjects must have previously received at least 3 anti-myeloma regimens. subjects must have documented disease progression (according to imwg criteria) during or within 12 months of completing their last anti-myeloma regimen prior to study entry; and prior regimens must have included proteasome inhibitor (pi) and immunomodulatory drug (imid). 3. measurable disease as defined by the protocol 4. ecog score is 0 or 1. 5. expected survival time ≥12 weeks. exclusion criteria: 1. patients suffering from graft-versus-host disease (gvhd) or requiring immunosuppressants drugs. 2. patients who received autologous hematopoietic stem cell transplantation (asct) or prior allogeneic hematopoietic stem cell transplantation (allo-hsct) within 12 weeks prior to mononuclear cell collection. 3. no unmobilized mononuclear cells can be collected for car t cell production. 4. screening subjects who were receiving systemic steroids during the previous 7 days or who were determined by the investigator to require long-term systemic steroid use during treatment (except for inhaled or topical use, except at doses \< 10mg/ day). 5. patients with a history of hypertension that cannot be controlled by medication (blood pressure ≥140/90 mmhg).
redirecting immune, lipid and metabolic drivers of early cardiovascular disease: the reset cohort study

Conditions: Cardiovascular Diseases; Metabolic Syndrome; Non-Alcoholic Fatty Liver Disease

Summary: project reset is a singapore national medical research council large collaborative grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early cardiovascular disease. reset incorporates a nested randomised controlled trials (rct) to test the use of a combined digital wearable and ai-human symbiotic lifestyle intervention to halt or reverse the progression of early disease.


Eligibility criteria:
inclusion criteria: * 40-70 years old * ascvd (atherosclerotic cardiovascular disease) score of 5% and higher exclusion criteria: * previous major cardiovascular disease (myocardial infarction, heart failure, ischemic stroke) * limited life expectancy * other ongoing unstable medical conditions * pregnant women
adapting a model for veterans on a psychiatric inpatient unit

Conditions: Conditions: Serious Mental Illness

Summary: this randomized controlled study tests an adapted critical time intervention model for veterans discharged from a psychiatric inpatient unit. it is hypothesized that veterans on the inpatient unit who are assigned to such a community-based team will have shorter lengths of inpatient stay and better mental health. there have been few developments of community-based models of care in the post-deinstitutionalization era of short inpatient stays and the results of the study may inform how inpatient stays can be further reduced.


Eligibility criteria:
inclusion criteria: 1. admitted to the psychiatric inpatient unit for at least 4 days 2. willing to participate in community-based treatment exclusion criteria: 1. actively suicidal or homicidal 2. dementia 3. drug or alcohol detoxification 4. physician emergency certificate
digestion of foods consumed in africa

Conditions: Obesity and Other Hyperalimentation

Summary: as populations become urbanized in africa, the change to a more westernized diet has been associated with rise in obesity and related metabolic syndrome diseases. the current study shows that in the west african sahel, these replacement starchy staple foods have fast gastric emptying compared to traditional sorghum and millet foods; and implies that the latter could be beneficial in lowering glycemic response, providing energy from a meal over a longer time, and providing a satiety effect. knowledge of this attribute of sorghum and millet foods could be useful to improve their image in west african cities to increase their consumption and to improve markets for local smallholder farmers.

as suggested by anecdotal evidence that traditional malian sorghum and millet foods are filling and provide sustained energy, we hypothesized that gastric emptying rates of sorghum and millet foods are slow, particularly compared to non-traditional starchy foods (white rice, potato, wheat pasta) that are now commonly consumed in urban areas of the west african sahel. a broader purpose for the study was to understand whether sorghum and millet foods have positive health attributes that can be promoted in urban areas to provide better markets for local farmers. two human trials of similar design were conducted approximately one year apart. the carbon 13 (13c)-labelled octanoic acid breath test method was used to measure gastric emptying rate, and subjective pre-test and satiety response questionnaires were used. in the first study, 14 healthy volunteers in bamako, mali participated in a crossover design to test eight starchy foods for gastric emptying rate and satiety feelings. the second study with six volunteers was done to correct for endogenous 13c differences in the starch component of the foods.

Eligibility criteria:
inclusion criteria: * normal body mass index (18 kg/m2 ≤ bmi ≤ 25 kg/m2) exclusion criteria: * under any medication * history of any gastrointestinal disease or surgery * diabetes * smoker
metastases of cutaneous squamous cell carcinoma in organ transplant recipients. the "scope-itscc metastases study"

Conditions: Squamous Cell Carcinoma

Summary: the investigators hypothesize that a low number of scc in otr will metastasize.

in a large international multicenter prospective observational study a total number of 1000 otr (organ transplant recipients) with a histologically proven cutaneous scc (squamous cell carcinoma) will be included in 10 centers and followed during 2 years to establish the cumulative incidence of metastases in otr with cutaneous scc.

Eligibility criteria:
inclusion criteria: * organ-transplant recipients (otr). * histologically proven cutaneous invasive scc at time of inclusion exclusion criteria: * lack of consent. * history of metastases of cutaneous scc
evaluation of tolerability of adjuvant cisplatin/docetaxel in completely resected stage ib/ii non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: the aim of this study is to evaluate the tolerability (in terms of drug delivery and toxicity) of four cycles of adjuvant docetaxel plus cisplatin in patients with completely resected stage ib-ii non-small cell lung cancer. to avoid a selection bias, eligible patients will be randomised to receive cisplatin/docetaxel or cisplatin/vinorelbine.


Eligibility criteria:
inclusion criteria: * completely resected pathological stage ib or ii nsclc * adequate haematological, renal and liver function and condition exclusion criteria: * previous chemo or radiotherapy for nsclc * bronchoalveolar cell subtype * second active primary malignancy or serious concomitant medical disease * difficulties with adequate follow-up

Keywords: non-small cell lung cancer nsclc adjuvant chemotherapy for completely resected nsclc
the setting and effect evaluation of qt in nicu

Conditions: Very Low Birth Weight Infant

Summary: in order to create a better environment for growth and development for very low birth weight infants(vlbwis), investigators introduce quiet time, which is an intervention method that reduces environmental noise in the ward and centralizes medical and nursing operations. by analyzing the weight gain of vlbwis in the intervention group and the control group during hospitalization, the effect of setting a quiet time in the nicu on improving the growth and development of vlbwis is evaluated.


Eligibility criteria:
inclusion criteria: * birth weight \<1500g; * admit within 24 hours of birth; * the guardian signs the informed consent. exclusion criteria: * newborn with severe congenital malformations or various chromosomal diseases, genetic metabolic diseases, severe neurological diseases; * newborn who do not achieve discharge or death at the end of the study period.

Keywords: quiet time weight
iontophoretic application of terbinafine gel to the large toe nail

Conditions: Onychomycosis

Summary: terbinafine is recognized as one of the most effective drugs for the treatment of toe nail fungus (onychomycosis). this trial will be the first test of a new device to improve the delivery of terbinafine directly to the toe nail. the device uses a low level of electric current, iontophoresis, to "push" the terbinafine into the nail. the study will involve a single application of terbinafine, in a gel form, with the iontophoretic device. the treatment will be applied to the surface of both large toenails of healthy subjects. subjects will be asked to report any sensations in the nail or surrounding skin experienced during or after treatment. samples from the edge of the treated toe nail will be taken at 2-4 week intervals to measure how much terbinafine was delivered to the nails, and blood samples will be taken for the first 24 hours after treatment to determine how much, if any, terbinafine was absorbed into the subjects's body. observations will also be made of the treated toes to look for any irritation of the surrounding skin due to the treatment.


Eligibility criteria:
inclusion criteria: * male and female volunteers between 18 and 75 years of age, inclusive. exclusion criteria: * subjects with pacemakers or automatic implantable cardioverter/defibrillator * subjects with an implantable electronic device. * subjects with a history of diabetes. * subjects with a history of onychomycosis or an abnormal appearing nail on the great toe * subject using systemic antifungal medications within 6 months prior to study enrollment. * subject using prescription topical antifungal medications for toenail fungus within 3 months or other commercially available medications for toenail fungus applied directly to the toenail within 1 week prior to study enrollment. * subject with a history of allergic or adverse response to terbinafine or any related anti-fungal drug * participation in a previous clinical trial involving an investigational drug or device within 30 days prior to study enrollment. * subject requires chronic use of analgesics, pain medication, or non-steroidal anti-inflammatory agents (nsaids). * in females of childbearing potential, a positive urine pregnancy test at screening and just prior to dosing. * nursing mothers. * subject with a history of alcoholism or drug abuse within the preceding 12 months.

Keywords: iontophoresis terbinafine onychomycosis